Stockreport

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday? [Yahoo! Finance]

Trevi Therapeutics, Inc.  (TRVI) 
PDF 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) patients with chronic cough, which requires no change to the current sample size for the trial (N=160) The CORAL [Read more]